Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2009 |
| End Date: | December 2011 |
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Doxorubicin has been an integral part of the treatment of women with breast cancer for many
years. Since amrubicin may have more activity than doxorubicin, as well as less
cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be
a priority. In this Phase II study, the investigators propose an evaluation of single-agent
amrubicin as second- or third-line treatment for women with metastatic breast cancer.
This will be a phase I/II study where phase I will evaluate the maximum tolerated dose of
amrubicin, and phase II will assess the progression free survival of patients with
HER2-negative metastatic breast cancer using the dose established in the phase I portion.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials